IP Library Granted Patent US 10,801,009
Granted Patent B2
US 10,801,009 · App. 15/527,046 · Granted Oct 13, 2020

Cosmetic composition for improving condition of skin, containing cell culture medium, epidermal growth factor and bovine serum albumin

Inventors: Chan Wha Kim (Seoul, KR); Young Joon Kim (Tenafly, NJ); Hyun Jung Kim (Seoul, KR)
Assignee: BIOCOZ GLOBAL KOREA CORP.
C12N5/0018A61K8/64A61K38/1808A61K38/385A61Q19/00A61Q19/08C12N5/0037C12N5/06C12Q1/68C12N2500/14C12N2500/16C12N2500/46C12N2500/76C12N2501/11
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,801,009
App. No.
15/527,046
Granted
Oct 13, 2020
Kind
B2
Abstract

The present invention relates to: a cosmetic composition for improving the condition of the skin, containing, as active ingredients, a cell culture medium, an epidermal growth factor and a bovine serum albumin; a method for improving the condition of the skin by using the same; and a method for preventing or treating skin diseases. According to the present invention, the cosmetic composition can exhibit excellent wrinkle-reducing and wound-healing effects even when only a small amount of EGF is used, and thus can be useful in improving the condition of the skin or in preventing or treating skin diseases.

Claims (16)

1. A method for improving a skin condition of a subject in need thereof, comprising applying to skin of the subject a composition comprising:

a) a cell culture medium;

b) 0.4 to 0.8 ng/mL of epidermal growth factor (EGF); and

c) 10 to 100 μg/mL of bovine serum albumin (BSA),

wherein the a) cell culture medium is a fetal bovine serum-free medium,

wherein the improvement of a skin condition is selected from the group consisting of inhibition of wrinkle occurrence, inhibition of skin aging, improvement of skin elasticity, skin regeneration, injury or wound healing, and a combination thereof; and

wherein the subject in need thereof is a mammal.

2. The method of claim 1 , wherein the cell culture medium is a mammalian cell culture medium.

3. The method of claim 2 , wherein the mammalian cell culture medium is selected from the group consisting of DMEM/F-12 (Dulbecco's Modified Eagle's Medium/Nutrient Mixture F-12), DMEM, and MEM α (Minimum Essential Medium α).

4. The method of claim 1 , wherein the composition further comprises a component selected from the group consisting of an amino acid, a vitamin, a carbon source, an inorganic salt, and a combination thereof.

5. The method of claim 4 , wherein the amino acid is selected from the group consisting of glycine, L-alanine, L-arginine hydrochloride, L-asparagine-monohydrate, L-aspartic acid, L-cysteine hydrochloride-monohydrate, L-cysteine 2HCl, L-glutamic acid, L-glutamine, L-histidine hydrochloride-monohydrate, L-isoleucine, L-leucine, L-lysine hydrochloride, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine disodium dihydrate, L-valine, L-histidine, L-tyrosine disodium salt, and a mixture thereof.

6. The method of claim 4 , wherein the vitamin is selected from the group consisting of biotin, calcium D-pantothenate, folic acid, niacinamide, pyridoxine hydrochloride, riboflavin, thiamine hydrochloride, vitamin B12, choline chloride, i-inositol, ascorbic acid and a mixture thereof.

7. The method of claim 4 , wherein the carbon source is selected from the group consisting of D-glucose (dextrose), sodium pyruvate, hyphoxanthin Na, thymidine, linoleic acid, lipoic acid, adenosine, cytidine, guanosine, uridine, 2′-deoxyadenosine, 2′-deoxycytidine HCl, 2′-deoxyguanosine, and a mixture thereof.

8. The method of claim 4 , wherein the inorganic salt is selected from the group consisting of anhydrous calcium chloride (CaCl 2 ), copper sulfate pentahydrate (CuSO 4 -5H 2 O), ferric sulfate heptahydrate (FeSO 4 -7H 2 O), anhydrous magnesium chloride, anhydrous magnesium sulfate (MgSO 4 ), potassium chloride (KCl), sodium chloride (NaCl), anhydrous disodium hydrogen phosphate (Na 2 HPO 4 ), sodium hydrogen phosphate monohydrate (NaH 2 PO 4 -H 2 O), zinc sulfate heptahydrate (ZnSO 4 -7H 2 O), ferric nitrate nonahydrate (Fe(NO 3 ) 3 ·9H 2 O), sodium bicarbonate (NaHCO 3 ), and a mixture thereof.

9. The method of claim 4 , wherein the composition comprises 1.110 to 1.606 g/L of an amino acid, 0.027 to 0.060 g/L of a vitamin, 1.201 to 4.625 g/L of a carbon source and 9.838 to 10.923 g/L of an inorganic salt.

10. The method of claim 1 , wherein the mammal is human.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 15, 2026
From: BIOCOZ GLOBAL PTE. LTD.
To: BG PHARMACEUTICAL, INC.
Reel/Frame 075422/0955 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2022
From: BIOCOZ GLOBAL KOREA CORP.
To: BIOCOZ GLOBAL PTE. LTD.
Reel/Frame 062186/0944 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2017
From: KIM, CHAN WHA; KIM, YOUNG JOON; KIM, HYUN JUNG
To: BIOCOZ GLOBAL KOREA CORP.
Reel/Frame 042392/0086 →
Continuity (2)
Provisional Application 62080708 · Nov 17, 2014
Related Publication 20170355952A1 · Dec 14, 2017